Hypoparathyroidism Therapy Could Improve Kidney Health
Long-term data suggests this hormone-replacement therapy helps adults maintain kidney function and reduce supplement needs.
Updated on Oct. 26, 2026 in Diabetes
Live Poll
Would you trust a new medical therapy over long-standing conventional treatments for your health?
New trial results suggest that TransCon PTH therapy may provide sustained kidney function improvements for patients with hypoparathyroidism. The data, covering five years of treatment, showed stable renal health and decreased urine calcium levels among 139 trial participants.
Why it matters
Hypoparathyroidism often requires high doses of calcium and vitamin D that can damage the kidneys over time. These results indicate a potential treatment approach that mimics natural hormones to stabilize renal function while reducing the need for conventional supplements.
A pooled analysis of 139 patients from the PaTH Forward and PaTHway trials demonstrated a mean eGFR improvement of 9.6 mL/min/1.73 m2 at 52 weeks. Researchers observed a stable eGFR slope of 0.28 mL/min/1.73 m2 per year through 266 weeks, though long-term cardiovascular data is still pending.
The players
Ascendis Pharma
A Copenhagen-based biopharmaceutical company focused on developing prodrug therapies for endocrine disorders.
The details
TransCon PTH works by continuously releasing active parathyroid hormone into the body, matching the physiological rhythm of the hormone 24 hours a day. This balanced approach helps restore normal calcium handling, which reduces the toxic load on the kidneys typically seen with standard high-dose calcium and vitamin D regimens. By achieving metabolic stability, most patients were able to discontinue supplemental active vitamin D and calcium therapies entirely.
Timeline
Week 26 marked the normalization of 24-hour urine calcium excretion for trial participants.
Week 52 saw clinically meaningful eGFR improvements in 68.9% of the treated patients.
October 26, 2026, was the date new trial data was presented at Kidney Week 2026.
Week 266 served as the final trial visit for the open-label extension study.
Health Landscape
The PaTH Forward and PaTHway trials have defined the current clinical understanding of hormone-replacement efficacy in patients with hypoparathyroidism. These results update the longitudinal safety and efficacy profile previously established by the same research program.
Patients currently managing hypoparathyroidism through high-dose calcium or vitamin D should discuss the potential long-term kidney risks with their endocrinologist. Monitoring eGFR and 24-hour urine calcium levels is a critical step in assessing whether current management strategies are adequately protecting renal health.
The takeaway
Restoring natural hormone balance may offer a path toward protecting kidney function in those with hypoparathyroidism. Patients should ask their doctor how their current calcium and vitamin D regimen affects their long-term renal health and if newer, hormone-stabilizing therapies might be appropriate.
Further reading
For more information on managing endocrine-related conditions, visit our Diabetes section.
Live Poll
Would you trust a new medical therapy over long-standing conventional treatments for your health?
